Indegene Ltd Stock Price Today (NSE: INDGN)
Fundamental Score
Indegene Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Indegene Ltd share price today is ₹434.60, down 1.77% on NSE/BSE as of 30 March 2026. Indegene Ltd (INDGN) is a Mid-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹12.66K (Cr). The 52-week high for INDGN share price is ₹632.90 and the 52-week low is ₹414.00. At a P/E ratio of 28.40x, INDGN is currently trading below its industry average P/E of 45.95x. The company has a Return on Equity (ROE) of 20.59% and a debt-to-equity ratio of 0.04.
Indegene Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Indegene Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Indegene Share Price: A Growth Strategy Financial Analysis
The Healthcare Research, Analytics & Technology sector is experiencing a paradigm shift, moving towards deeper integration of data-driven insights to optimize clinical trials and market access strategies. This backdrop provides a crucial context for understanding the potential of companies like Indegene. A detailed financial analysis is key to understanding the growth outlook for Indegene share price. This analysis delves into Indegene's current valuation and financial health to assess its potential in this evolving landscape.
At a current price of ₹489.25, Indegene's shares trade at a Price-to-Earnings (PE) ratio of 28.4. While a PE ratio offers a snapshot of relative value, it's critical to compare this with sector peers. Consider the contrasting management quality and strategic execution differences between Indegene Ltd and
NOVELIX PHARMACEUTICALS LIMITE. Ultimately, superior management can translate to greater operational efficiency and shareholder value, influencing relative valuations over time. Careful consideration of the peer group PE must be made.A particularly noteworthy aspect of Indegene's financial profile is its Return on Capital Employed (ROCE) of 24.8%. This high ROCE is a strong indicator of efficient capital allocation and profitability. A consistent ROCE above its cost of capital strengthens the company's economic moat, suggesting a sustainable competitive advantage. The high ROCE signals to investors Indegene's future opportunities.
This financial analysis, looking into Indegene share price, forms part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra. The analysis remains observational, and does not constitute buy/sell recommendations. Further in-depth study is necessary to determine suitability of the stock for an investment portfolio.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Indegene Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDGN across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (20.59%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.97%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 28.40 vs Industry: 45.95)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (17.09%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (34.59% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (15.71% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (67.93% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (43.09x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1444.04 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Indegene Ltd Financial Statements
Comprehensive financial data for Indegene Ltd including income statement, balance sheet and cash flow
About INDGN (Indegene Ltd)
Indegene Ltd is a global healthcare solutions provider that is revolutionizing the way life sciences companies operate. Focusing on the intersection of healthcare, technology, and ...commercialization, Indegene empowers biopharmaceutical, emerging biotech, and medical device organizations to achieve their strategic goals. With a deep understanding of the complex healthcare landscape, Indegene offers a comprehensive suite of solutions, spanning from clinical trial optimization to digital marketing and sales force enablement. They are committed to driving innovation and efficiency across the entire product lifecycle, ultimately accelerating the delivery of life-saving therapies to patients in need. At the core of Indegene's capabilities lies a robust foundation in data analytics, artificial intelligence, and digital technologies. They leverage these tools to uncover actionable insights, optimize marketing campaigns, and personalize patient engagement strategies. Indegene helps clients to transform complex medical data into easily digestible information for patients, healthcare professionals, and payers. Through its enterprise commercial and medical solutions, Indegene partners with organizations to navigate the ever-evolving regulatory landscape and optimize their market access strategies. They also provide medical and clinical solutions that include but not limited to literature reviews, publications and more. Indegene is a catalyst for change in the healthcare industry, helping organizations embrace the power of digital transformation to improve patient outcomes. By combining deep industry expertise with cutting-edge technologies, Indegene is uniquely positioned to empower life sciences companies to thrive in the digital age. Through their omnichannel activation services, they support companies to effectively communicate with their target audiences across multiple channels, building trust and brand loyalty. Their dedication to excellence and customer-centric approach makes them a trusted partner for organizations seeking to unlock the full potential of their life-saving products.
Company Details
Key Leadership
Corporate Events
Latest News
INDGN Share Price: Frequently Asked Questions
What is the current share price of Indegene Ltd (INDGN)?
As of 30 Mar 2026, 12:06 pm IST, Indegene Ltd share price is ₹434.60. The INDGN stock has a market capitalisation of ₹12.66K (Cr) on NSE/BSE.
Is INDGN share price Overvalued or Undervalued?
INDGN share price is currently trading at a P/E ratio of 28.40x, compared to the industry average of 45.95x. Based on this relative valuation, the Indegene Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of INDGN share price?
The 52-week high of INDGN share price is ₹632.90 and the 52-week low is ₹414.00. These values are updated daily from NSE/BSE price data.
What factors affect the Indegene Ltd share price?
Key factors influencing INDGN share price include quarterly earnings growth (Sales Growth: 17.09%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Indegene Ltd a good stock for long-term investment?
Indegene Ltd shows a 5-year Profit Growth of 67.93% and an ROE of 20.59%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.04 before investing in INDGN shares.
How does Indegene Ltd compare with its industry peers?
Indegene Ltd competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare INDGN share price P/E of 28.40x and ROE of 20.59% against the industry averages to determine competitive standing.
What is the P/E ratio of INDGN and what does it mean?
INDGN share price has a P/E ratio of 28.40x compared to the industry average of 45.95x. Investors pay ₹28 for every ₹1 of annual earnings.
How is INDGN performing according to Bull Run's analysis?
INDGN has a Bull Run fundamental score of 66.8/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does INDGN belong to?
INDGN operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Indegene Ltd share price.
What is Return on Equity (ROE) and why is it important for INDGN?
INDGN has an ROE of 20.59%, which indicates excellent management efficiency. ROE measures how efficiently Indegene Ltd generates profits from shareholders capital.
How is INDGN debt-to-equity ratio and what does it indicate?
INDGN has a debt-to-equity ratio of 0.04, which indicates conservative financing with low financial risk.
What is INDGN dividend yield and is it a good dividend stock?
INDGN offers a dividend yield of 0.38%, meaning you receive ₹0.38 annual dividend for every ₹100 invested in Indegene Ltd shares.
How has INDGN share price grown over the past 5 years?
INDGN has achieved 5-year growth rates of: Sales Growth 34.59%, Profit Growth 67.93%, and EPS Growth 15.71%.
What is the promoter holding in INDGN and why does it matter?
Promoters hold 0.00% of INDGN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Indegene Ltd.
What is INDGN market capitalisation category?
INDGN has a market capitalisation of ₹12660 crores, placing it in the Mid-cap category.
How volatile is INDGN stock?
INDGN has a beta of N/A. A beta > 1 suggests the Indegene Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is INDGN operating profit margin trend?
INDGN has a 5-year average Operating Profit Margin (OPM) of 18.97%, indicating the company's operational efficiency.
How is INDGN quarterly performance?
Recent quarterly performance shows Indegene Ltd YoY Sales Growth of 17.09% and YoY Profit Growth of 11.34%.
What is the institutional holding pattern in INDGN?
INDGN has FII holding of 11.30% and DII holding of 6.95%. Significant institutional holding often suggests professional confidence in the Indegene Ltd stock.